Identification of a novel ALK variant intrinsically resistant to crizotinib

Anai S., Masafumi T., Ando N., et al. A case of lung adenocarcinoma resistant to crizotinib harboring a novel EML4-ALK variant, exon 6 of EML4 fused to exon 18 of ALK. (2016);11(10):126–128. doi:10.1016/j.jtho.2016.07.008. Barlesi, 2016, Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French cooperative thoracic intergroup (IFCT), Lancet, 387, 1415, 10.1016/S0140-6736(16)00004-0 Doebele R.C., Pilling A.B., Aisner D.L., et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non - small cell lung cancer. 2012;18(5):1472–1483. doi:10.1158/1078-0432.CCR-11-2906. Gaughan, 2011, Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities, Ther. Adv. Med. Oncol., 3, 113, 10.1177/1758834010397569 Landrum, 2018, ClinVar: improving access to variant interpretations and supporting evidence, Nucleic Acids Res., 46, D1062, 10.1093/nar/gkx1153 Network NCC. Non-small cell lung cancer (version3.2020). https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Published 2020. Accessed April 10, 2020. Tate, 2019, COSMIC: the catalogue of somatic mutations, Cancer Nucleic Acids Res., 47, D941, 10.1093/nar/gky1015